X4 Pharmaceuticals (FRA:48Q) Total Assets : €103.21 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is X4 Pharmaceuticals Total Assets?

X4 Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was €103.21 Mil.

During the past 12 months, X4 Pharmaceuticals's average Total Assets Growth Rate was 1.00% per year. During the past 3 years, the average Total Assets Growth Rate was -9.20% per year. During the past 5 years, the average Total Assets Growth Rate was 29.00% per year.

During the past 9 years, X4 Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 114.70%. The lowest was -9.20%. And the median was 56.45%.

Total Assets is connected with ROA %. X4 Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 was -159.92%. Total Assets is also linked to Revenue through Asset Turnover. X4 Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

X4 Pharmaceuticals Total Assets Historical Data

The historical data trend for X4 Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

X4 Pharmaceuticals Total Assets Chart

X4 Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

144.63

101.00

103.70

146.87

135.04

X4 Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															116.19	160.05	162.38	135.04	103.21

X4 Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

X4 Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	46.858	+	88.178
	=	135.04

X4 Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	0.953	+	102.254
	=	103.21

X4 Pharmaceuticals (FRA:48Q) Total Assets Explanation

Total Assets is connected with ROA %.

X4 Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-190.5	/	( (135.036	+	103.207)	/ 2 )
	=	-190.5	/	119.1215
	=	-159.92 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

X4 Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (135.036	+	103.207)	/ 2 )
=	0	/	119.1215
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

X4 Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of X4 Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

X4 Pharmaceuticals (FRA:48Q) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » X4 Pharmaceuticals Inc (FRA:48Q) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

XFOR:USA 48Q:Germany

Address

61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134

Website

https://www.x4pharma.com

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream.

X4 Pharmaceuticals (FRA:48Q) Headlines

No Headlines